|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Felodipine#Pharmacology]] |
| {{Felodipine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Description==
| |
| | |
| PLENDIL (felodipine) is a calcium antagonist (calcium channel blocker). Felodipine is a dihydropyridine derivative that is chemically described as ± ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate. Its empirical formula is C18H19Cl2NO4 and its structural formula is:
| |
| {|
| |
| |[[File:felodipine02.jpg|thumb|800px]]
| |
| |}
| |
| | |
| {|
| |
| |[[File:felodipine07.png|thumb|800px]]
| |
| |}
| |
| Felodipine is a slightly yellowish, crystalline powder with a molecular weight of 384.26. It is insoluble in water and is freely soluble in dichloromethane and ethanol. Felodipine is a racemic mixture. | |
| Tablets PLENDIL provide extended release of felodipine. They are available as tablets containing 2.5 mg, 5 mg, or 10 mg of felodipine for oral administration. In addition to the active ingredient felodipine, the tablets contain the following inactive ingredients: Tablets PLENDIL 2.5 mg — hydroxypropyl cellulose, lactose, FD&C Blue 2, sodium stearyl fumarate, titanium dioxide, yellow iron oxide, and other ingredients. Tablets PLENDIL 5 mg and 10 mg — cellulose, red and yellow oxide, lactose, polyethylene glycol, sodium stearyl fumarate, titanium dioxide, and other ingredients.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLENDIL (FELODIPINE) TABLET, EXTENDED RELEASE [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2aad9cdf-6431-4661-5cb4-f69e735f47e4 | publisher = | date = | accessdate = 28 February 2014 }}</ref>
| |
| | |
| ==References ==
| |
| {{Reflist|2}}
| |
| | |
| {{Calcium channel blockers}}
| |
| | |
| [[Category:Calcium channel blockers]]
| |
| [[Category:Dihydropyridines]]
| |
| [[Category:Carboxylate esters]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |